FY2026 EPS Estimates for argenx SE Boosted by Leerink Partnrs (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Research analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of argenx in a research note issued to investors on Saturday, June 22nd. Leerink Partnrs analyst T. Smith now anticipates that the company will earn $6.30 per share for the year, up from their previous estimate of $5.86. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The firm had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. During the same quarter last year, the company earned ($0.52) earnings per share.

ARGX has been the subject of several other reports. Wells Fargo & Company increased their price objective on shares of argenx from $478.00 to $542.00 and gave the stock an “overweight” rating in a research report on Monday. William Blair reiterated a “market perform” rating on shares of argenx in a research report on Monday, June 17th. Truist Financial increased their target price on shares of argenx from $440.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $448.00 target price on shares of argenx in a research note on Monday. Finally, Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Tuesday, March 26th. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $525.42.

argenx Stock Down 1.3 %

ARGX opened at $445.88 on Tuesday. argenx has a twelve month low of $327.73 and a twelve month high of $550.76. The company has a fifty day moving average of $379.85 and a 200-day moving average of $386.89. The stock has a market cap of $26.50 billion, a PE ratio of -78.78 and a beta of 0.65.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ARGX. PNC Financial Services Group Inc. lifted its position in shares of argenx by 6.7% during the third quarter. PNC Financial Services Group Inc. now owns 1,341 shares of the company’s stock valued at $659,000 after purchasing an additional 84 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of argenx during the third quarter valued at about $433,000. Envestnet Asset Management Inc. lifted its position in shares of argenx by 144.5% during the third quarter. Envestnet Asset Management Inc. now owns 43,887 shares of the company’s stock valued at $21,576,000 after purchasing an additional 25,940 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of argenx by 42.9% during the third quarter. Acadian Asset Management LLC now owns 806 shares of the company’s stock valued at $396,000 after purchasing an additional 242 shares in the last quarter. Finally, Mariner LLC increased its holdings in argenx by 36.1% during the third quarter. Mariner LLC now owns 2,764 shares of the company’s stock worth $1,359,000 after buying an additional 733 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.